At a glance
- Originator Procter & Gamble
- Class Antibacterials
- Mechanism of Action Cell wall inhibitors; DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 11 Jun 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 16 Oct 1998 A preclinical study has been added to the pharmacokinetics section
- 21 Nov 1997 New profile